Form 8-K - Current report:
SEC Accession No. 0001193125-24-273467
Filing Date
2024-12-09
Accepted
2024-12-09 16:45:54
Documents
21
Period of Report
2024-12-09
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d837203d8k.htm   iXBRL 8-K 30951
2 EX-1.1 d837203dex11.htm EX-1.1 161740
3 EX-5.1 d837203dex51.htm EX-5.1 7788
4 EX-99.1 d837203dex991.htm EX-99.1 44909
8 GRAPHIC g837203g1207024953393.jpg GRAPHIC 1499
9 GRAPHIC g837203g1207024953548.jpg GRAPHIC 5930
10 GRAPHIC g837203g1207025114990.jpg GRAPHIC 2997
11 GRAPHIC g837203g1207025115271.jpg GRAPHIC 21892
12 GRAPHIC g837203g1207025115513.jpg GRAPHIC 19911
  Complete submission text file 0001193125-24-273467.txt   497806

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA rgnx-20241209.xsd EX-101.SCH 2845
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE rgnx-20241209_lab.xml EX-101.LAB 17236
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rgnx-20241209_pre.xml EX-101.PRE 10809
23 EXTRACTED XBRL INSTANCE DOCUMENT d837203d8k_htm.xml XML 3500
Mailing Address 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850
Business Address 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 240-552-8181
REGENXBIO Inc. (Filer) CIK: 0001590877 (see all company filings)

EIN.: 471851754 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37553 | Film No.: 241535656
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)